- Home
- GUTS vs XTNT Comparison
GUTS vs XTNT Comparison
Compare GUTS & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- XTNT
- Stock Information
- Founded
- GUTS 2010
- XTNT N/A
- Country
- GUTS United States
- XTNT United States
- Employees
- GUTS N/A
- XTNT N/A
- Industry
- GUTS
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUTS
- XTNT Health Care
- Exchange
- GUTS NYSE
- XTNT Nasdaq
- Market Cap
- GUTS 54.8M
- XTNT 60.9M
- IPO Year
- GUTS 2024
- XTNT N/A
- Fundamental
- Price
- GUTS $1.33
- XTNT $0.45
- Analyst Decision
- GUTS Buy
- XTNT Strong Buy
- Analyst Count
- GUTS 1
- XTNT 1
- Target Price
- GUTS $10.00
- XTNT $3.00
- AVG Volume (30 Days)
- GUTS 292.5K
- XTNT 66.0K
- Earning Date
- GUTS 05-12-2025
- XTNT 05-14-2025
- Dividend Yield
- GUTS N/A
- XTNT N/A
- EPS Growth
- GUTS N/A
- XTNT N/A
- EPS
- GUTS N/A
- XTNT N/A
- Revenue
- GUTS $93,000.00
- XTNT $117,267,000.00
- Revenue This Year
- GUTS N/A
- XTNT $15.56
- Revenue Next Year
- GUTS N/A
- XTNT $22.39
- P/E Ratio
- GUTS N/A
- XTNT N/A
- Revenue Growth
- GUTS N/A
- XTNT 28.44
- 52 Week Low
- GUTS $0.87
- XTNT $0.33
- 52 Week High
- GUTS $7.89
- XTNT $0.97
- Technical
- Relative Strength Index (RSI)
- GUTS 56.78
- XTNT 49.25
- Support Level
- GUTS $0.87
- XTNT $0.34
- Resistance Level
- GUTS $1.39
- XTNT $0.43
- Average True Range (ATR)
- GUTS 0.12
- XTNT 0.05
- MACD
- GUTS 0.05
- XTNT 0.01
- Stochastic Oscillator
- GUTS 88.39
- XTNT 68.75
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.